You are using an older browser version. Please use a supported version for the best MSN experience.

Alberta Health to cover Zolgensma, a $2.8-million gene therapy treatment, on case-by-case basis

Zolgensma is a new gene therapy for SMA approved by Health Canada in December. It's administered by intravenous infusion to replace a missing or faulty gene, and a one-time treatment costs $2.8 million.

UP NEXT

UP NEXT

image beaconimage beaconimage beacon